Latest / The Series A Show with Fexingo: Early-Stage Funding, Pitch Decks, and Startup Milestones
Why Biotech Startups Are Moving to Pre-Filled Drug Trials
Episode 82 of The Series A Show explores a controversial new trend in early-stage biotech: pre-filling patient cohorts before the FDA officially signs off. Lucas and Luna dig into the case of a startup called Beacon Therapeutics, which enrolled 80% of its Phase 2 trial for a rare-eye-disease gene therapy before even filing an IND. They discuss why VCs like ARCH Venture Partners are funding this approach, how it cuts clinical-timeline risk, and why the FDA hasn't pushed back yet. The conversation draws on current data from the ARKG genomics ETF, which jumped nearly 18% this week on…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.